Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL5953988 | 1.00 | CA2 (0.33) | CA2CA1CA7CA13 | |
| SCHEMBL160 | 0.87 | CA2 (0.41) | CA2CA1CA7CA13 | |
| SCHEMBL758883 | 0.87 | CA2 (0.41) | CA2CA1CA7CA13 | |
| SCHEMBL758884 | 0.87 | CA2 (0.41) | CA2CA1CA7CA13 | |
| SCHEMBL6830251 | 0.84 | CA2 (0.39) | CA2CA1CA7CA13 | |
| SCHEMBL28351237 | 0.84 | CA2 (0.39) | CA2CA1CA7CA13 | |
| SCHEMBL6448264 | 0.84 | CA2 (0.39) | CA2CA1CA7CA13 | |
| SCHEMBL28816823 | 0.84 | CA2 (0.39) | CA2CA1CA7CA13 | |
| Hydrochloric Acid SCHEMBL29534663 | 0.84 | CA2 (0.39) | CA2CA1CA7CA13 | |
| SCHEMBL28423969 | 0.84 | CA2 (0.39) | CA2CA1CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116377016-A | High-voltage insulating material mold pollution cleaning system and method | 华北电力大学（保定） | 2023-07-04 | — | — | CN | claimed |
| US-12021195-B2 | Asymmetric electrolyte salts and batteries incorporating such salts | OHIO STATE INNOVATION FOUNDATION (US) | 2024-06-25 | — | — | US | disclosed |
| CN-116377016-A | High-voltage insulating material mold pollution cleaning system and method | 华北电力大学（保定） | 2023-07-04 | — | — | CN | disclosed |
| CN-115594569-A | Synthesis method of 2, 3-difluorophenetole negative liquid crystal compound | 重庆汉朗精工科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-106132928-B | Anil, the medical composition and its use containing the derivative | 橘生药品工业株式会社 | 2019-03-29 | — | — | CN | disclosed |
| CN-108059644-A | The electroluminescent organic material of a kind of naphthalene azepine dibenzo substitution as ligand and application thereof | 上海和辉光电有限公司 | 2018-05-22 | — | — | CN | disclosed |
| US-7223779-B2 | Azasugar derivative and drug containing the same as the active ingredient | CARNA BIOSCIENCES INC. (JP) | 2007-05-29 | — | — | US | disclosed |
| EP-0948511-B1 | CHEMICAL SYNTHESIS OF NUCLEOSIDES ANALOGS AND THEIR INCORPORATION INTO POLYNUCLEOTIDES | SIRNA THERAPEUTICS INC (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050154017-A1 | Novel azasugar derivative and drug containing the same as the active ingredient | CARNA BIOSCIENCES INC. (JP) | 2005-07-14 | — | — | US | disclosed |
| US-20050137221-A1 | Novel azasugar derivative and drug containing the same as the active ingredient | TSUKIDA TAKAHIRO (JP) | 2005-06-23 | — | — | US | disclosed |
| EP-1516872-A1 | NOVEL AZASUGAR DERIVATIVE AND DRUG CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Carna Biosciences Inc. (JP) | 2005-03-23 | — | — | EP | disclosed |
| US-6506888-B1 | Viricides, antitumor and anticarcinogenic agents | RIBOZYME PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6159951-A | 2'-O-amino-containing nucleoside analogs and polynucleotides | RIBOZYME PHARMACEUTICALS INC. (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0948511-A2 | CHEMICAL SYNTHESIS OF NUCLEOSIDES ANALOGS AND THEIR INCORPORATION INTO POLYNUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998028317-A2 | SYNTHESIS OF NUCLEOSIDES AND POLYNUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| EP-0655457-A1 | MORANOLINE DERIVATIVE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154017-A1 | Novel azasugar derivative and drug containing the same as the active ingredient | CDK8, DUT, CDK7 | CA2 4105/4885CA1 4554/4885CA7 2379/4885 |
| US-20050137221-A1 | Novel azasugar derivative and drug containing the same as the active ingredient | CDK8, DUT, CDK7 | CA2 4105/4885CA1 4554/4885CA7 2379/4885 |
| US-12021195-B2 | Asymmetric electrolyte salts and batteries incorporating such salts | HCN2, KCNN2, POTEE | CA2 163/4885CA1 168/4885CA7 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.